CVS Caremark to Drop J&J's Stelara, Prioritizing Biosimilars for Client Savings
CVS sits 41% above its 52-week low of $58.35.
Summary
CVS Health's pharmacy benefit management unit, Caremark, announced it will remove Johnson & Johnson's psoriasis drug Stelara from its main formularies starting July 1, opting instead for lower-cost biosimilar versions. This strategic move aims to deliver significant savings for clients and support broader, more affordable access to proven therapies, with most members paying $0 out-of-pocket for biosimilar alternatives. This decision aligns with CVS's broader efforts to manage healthcare costs, following recent news regarding its Aetna division's focus on standardizing prior authorizations and evaluating Medicare Advantage benefits. For CVS, this is a positive strategic step to enhance its PBM offering and drive value for clients, while for Johnson & Johnson, it represents a notable loss of formulary coverage for a key drug. Investors should monitor the financial implications for both companies and the broader trend of biosimilar adoption across the industry.
At the time of this announcement, CVS was trading at $82.17 on NYSE in the Life Sciences sector, with a market capitalization of approximately $105.1B. The 52-week trading range was $58.35 to $85.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.